Abstract: Programmed cell death 1/programmed cell death ligand (PD-1/PD-Ls) axis is crucial for the modulation of immune responses and self-tolerance.
P
rogrammed cell death 1/programmed cell death ligand (PD-1/PD-Ls) axis is crucial for the modulation of the immune system to reduce collateral tissue damage from the inflammatory response to infectious microorganisms in peripheral tissues. In addition, direct evidence that PD-1-deficient mice develop spontaneous autoimmune diseases suggests an inhibitory and regulatory role for PD-1/ PD-L interaction in T-cell responses and the maintenance of self-tolerance. 1, 2 PD-1 (CD279) is a cell surface receptor that belongs to the immunoglobulin superfamily and also a member of the extended CD28/CTLA-4 family. The extracellular region of PD-1 is 28% identical to CTLA-4, another immune checkpoint molecule. 1, 3 PD-1 is mainly expressed on activated T cells, whereas other non-T lymphocytes such as B cells and natural killer cells express PD-1 only upon induction. 4, 5 PD-1 is a costimulatory molecule and, once engaged by its ligands PD-Ls, PD-1 (probably along with the other cooperative pathways) inhibits kinases that are involved in T-cell activation through the phosphatase SHP2. 6 When T cells were exposed to chronic antigen stimulation such as chronic viral infection or cancer, high levels of persistent PD-1 expression is induced and leads to T-cell exhaustion or anergy.
PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), 2 physiological ligands for PD-1, have been identified as cell-surface glycoproteins belonging to the B7 family. [6] [7] [8] [9] These B7 family members share 37% sequence homology and are located within 100 kb of the genomic locus at 9p24, probably evolving through gene duplication. 9 In peripheral tissues, PD-L1 is primarily induced by interferon-g, from T helper 1 cells under inflammatory conditions.
In early studies, melanoma, ovarian, colon, and lung cancer tissues were reported to express high levels of PD-L1. 10 Subsequently, other human cancers such as esophageal, gastric, and hepatocellular carcinoma were reported to express PD-L1. Moreover, PD-L1 expression was linked to tumor aggressiveness and a poor clinical prognosis. [11] [12] [13] It was reported that aberrantly activated oncogenic signals induce PD-L1 expression on tumor cells and allow them to evade the host immune system by dampening antitumor immunity through anergy or apoptosis of antigen-specific T cells. 14, 15 Furthermore, PD-L1-expressing tumor-associated inflammatory cells (TAIs, which include macrophages and lymphocytes infiltrating and/or surrounding neoplastic tissue) are also reported to induce tumor immune evasion. [16] [17] [18] In the past decade, several immune checkpoint inhibitors (nivolumab and pembrolizumab for PD-1/PD-L inhibition; tremelimumab and ipilimumab for CTLA-4/ B7 inhibition) were introduced for the treatment of several cancer types to conquer tumor immune evasion. Recently, significant anticancer effects of nivolumab were demonstrated in phase 3 clinical trials for the treatment of non-small cell lung cancer (NSCLC) as well as other malignancies. [19] [20] [21] [22] PD-L1 expression, as detected by immunohistochemistry, is a potential biomarker to predict clinical response to PD-1/PD-L checkpoint inhibitors in the clinical setting. [19] [20] [21] [22] Several types of cancer have been analyzed for PD-L1 expression, but a comprehensive analysis, including rare germ cell and mesenchymal tumors, has not been performed. [10] [11] [12] [13] [23] [24] [25] The aim of this study was to evaluate potential utility of PD-L1 immunohistochemistry in diagnostic pathology and identify additional tumor types for PD-1/ PD-L axis inhibitor treatment.
MATERIALS AND METHODS
A total of 5536 anonymized tumors, including germ cell, epithelial, mesenchymal, melanocytic/neuroectodermal, and lymphohematopoietic tumors, and normal tissues derived from surgical specimens were assembled to multitumor blocks containing 30 to 70 rectangular tissue samples as previously described. 26 The size of tumor tissue samples was estimated to exceed the size of a single 0.6 mm 2 core by a factor of 10 to 15. All tumors, selected for this study, were extensively characterized histologically and immunohistochemically. In addition, a 10-week-old fetus was immunohistochemically analyzed.
The rabbit monoclonal antibody clones E1L3N (#13684) and 28-8 (ab205921) 27 For the detection of Epstein-Barr virus (EBV) infection, Bond Ready-to-Use ISH EBER Probe was used in Leica BondMax automation system according to the manufacturer instructions (Leica Biosystems).
The stained sections were independently evaluated by 2 pathologists (S.I. and M.M.). PD-L1 immunoreactivity in placental trophoblasts and peripheral nerves was used as external and internal positive controls, respectively. PD-L1 has been reported to be expressed on not only tumor cells but also dendritic cells and TAIs; therefore, we evaluated PD-L1 expression in both neoplastic cells and TAIs with a detection cutoff of 5%. 
RESULTS

Normal Tissues and Fetus
Among the normal adult tissue components, highest PD-L1 expression was detected in placental trophoblasts (Fig. 1A) . Macrophages such as alveolar ones, dendritic cells of lymphoid tissue, peripheral nerves, probably schwann cells, and smooth and skeletal muscle cells showed variable PD-L1 positivity (Fig. 1B) . Organs such as adrenal gland, brain, genitourinary tract, kidney, liver, lung, mammary gland, pancreas, salivary gland, and thyroid gland showed no PD-L1 expression. Fetal tissues with the exception of placental trophoblasts were also negative for PD-L1 expression.
Germ Cell Tumors
The results of PD-L1 immunostaining in germ cell tumors have been summarized in Table 1 . Choriocarcinomas were nearly uniformly positive for PD-L1 with a membrane pattern ( Fig. 2A) . Similarly, 1 placental site trophoblastic tumor and 6 mixed germ cell tumors of testis showed PD-L1 positivity in the trophoblastic cellular elements. Other germ cell tumors, such as seminoma, embryonal carcinoma, and yolk sac tumor showed PD-L1 expression (57% to 81%), only in TAIs, especially macrophages ( 
Other Epithelial Neoplasms
Expression status of PD-L1 in epithelial non-germ cell tumors is shown in Table 2 . Thymic tumors showed frequent PD-L1 expression. In thymomas, 79% of cases showed PD-L1 positivity in neoplastic epithelial cells, whereas tumor-associated thymocytes were negative for PD-L1 ( Fig. 3A and Table 2 ). Thymic carcinoma cells showed lower PD-L1 positivity than thymomas (38% of cases) ( Table 2) .
Squamous cell carcinoma cells of the tongue and tonsils ( Fig. 3B ) showed higher PD-L1 labeling (61% to 67% of cases), whereas those of esophagus showed lowest PD-L1 expression (39% of cases). No statistical correlation was detected between p16 and PD-L1 expression in any of the oral squamous cell carcinomas (Supplementary  Table S2 , Supplemental Digital Content 2, http://links. lww.com/PAS/A361). The former was most often detected in tonsillar carcinoma.
PD-L1 was only rarely expressed in colorectal adenocarcinoma cells (13% of cases, with 5% to 100% of positive cells, median 40%) ( Fig. 3C and Table 2 ). Seventeen percent of colorectal adenocarcinomas showed MMR deficiency (Fig. 3D ). Statistically positive correlation was detected between the MMR deficiency and PD-L1 expression in colorectal adenocarcinoma (Table 3) .
Gastric adenocarcinoma cells also showed rare PD-L1 expression (14% of cases, 5% to 100% of positive cells, median 40%; Fig. 3E and Table 2 ). In this study, 8% (15 of 180 cases) and 6% (11 of 190 cases) of gastric adenocarcinomas were determined as MMR-deficient and EBER-positive tumors, respectively (Fig. 3F) . MMR deficiency and EBER positivity were detected in a mutually exclusive manner. Statistically positive correlation was detected between the PD-L1 expression and MMR-deficient and/or EBER-positive status (Table 4) .
Neoplastic cells of endometrioid adenocarcinoma and serous carcinoma of the ovary, invasive ductal and lobular carcinomas of the breast, hepatocellular carcinoma, and prostate adenocarcinoma only rarely expressed PD-L1 (2% to 6% of cases) ( Table 2) .
In other epithelial tumors, PD-L1 expression was detected in neoplastic cells (5% to 36% of cases) or TAIs (1% to 59%). TAIs of Merkel cell carcinoma showed a high frequency of PD-L1 expression (59% of cases) (Supplementary Table S1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A360).
Hematopoietic and Lymphoid Tumors
PD-L1 expression in lymphohematopoietic tumors has been summarized in Table 5 . Ninety-six percent of classical Hodgkin lymphoma cases showed PD-L1 expression in 
com/PAS/A363).
A minor population of diffuse large B-cell lymphoma and natural killer and T-cell lymphoma cells showed positivity for PD-L1 (18% and 16% of cases, respectively). Although only 2 cases of diffuse large B-cell lymphoma showed EBER positivity, statistical correlation was detected between EBER and PD-L1 expression (Table 6 ). Neoplastic cells of mantle cell lymphoma, nodal marginal zone lymphoma, T-lymphoblastic and B-lymphoblastic lymphoma, follicular lymphoma, and small cell lymphoma showed no PD-L1 expression. Conversely, lymphoma-associated inflammatory cells showed frequent PD-L1 expression (29% to 75% of cases), except for small cell lymphoma (Supplementary Table S1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A360).
Mesenchymal and Neuroectodermal Tumors
PD-L1 expression in mesenchymal tumors has been summarized in Table 7 . Among mesenchymal tumors, the highest PD-L1 positivity was detected in peripheral schwannomas (89% of cases, 5% to 100% of positive cells, median 90%; Fig. 5A ). Gastric schwannomas showed less consistent and weaker PD-L1 expression than peripheral schwannomas (67% of cases, 5% to 100% of positive cells, median 90%). TAIs in schwannoma were negative for PD-L1 (Supplementary Table S1 , Supplemental Digital Content 1, http://links.lww.com/PAS/ A360). Neurofibroma showed less frequent positivity (44% of cases, 5% to 100% of positive cells, median 70%), whereas granular cell tumors were negative for PD-L1. Potential schwannoma mimics such as solitary fibrous tumor, fibrous histiocytoma, and perineurioma were all negative for PD-L1. In both malignant peripheral nerve sheath tumor (MPNST, Fig. 5B ) and neuroblastoma, 21% of cases showed PD-L1 expression. In neuroblastomas, PD-L1 expression was limited to the schwannian stroma.
Minor populations of embryonal rhabdomyosarcoma cells showed weak PD-L1 expression (17% of cases, 10% to 80% of positive cells, median 40%; Fig. 5C ). An isolated case of alveolar soft part sarcoma (9% of cases) showed membranous PD-L1 expression (Fig. 5D ). Rare malignant melanoma (17% of cases) and SDH-deficient gastrointestinal stromal tumor (13% of cases) expressed PD-L1. Other soft tissue tumors such as glomus tumor and synovial sarcoma were negative for PD-L1. In mesenchymal tumors, TAIs also showed much lower PD-L1 expression compared with carcinomas and lymphomas (Supplementary Table S1 , Supplemental Digital Content 1, http://links.lww.com/ PAS/A360).
DISCUSSION
In physiological conditions, the PD-1/PD-L axis is crucial for the regulation of immune responses to minimize collateral tissue damage as well as maintaining selftolerance. However, in neoplastic disease, once PD-Ls are aberrantly expressed on tumor cells and/or TAIs, they help tumor cells evade the host immune system and promote tumor growth. In the past decade, PD-1/PD-L immune checkpoint inhibitors have been introduced in anticancer therapy. [19] [20] [21] [22] To predict a clinical response to these drugs, PD-L1 immunohistochemical staining has been used as a potential biomarker. [19] [20] [21] [22] In this study, PD-L1 expression was immunohistochemically analyzed in normal and neoplastic tissue to assess potential diagnostic utility of PD-L1 immunohistochemistry and to identify specific neoplasms that may be amenable to anti-PD-1/PD-L immune checkpoint therapy.
In normal tissues, the most striking PD-L1 expression was detected in placental trophoblast (Fig. 1A) . Interestingly, the fetus showed no PD-L1 expression. These results reflect the nature of the trophoblast as a maternal-fetal barrier protecting the fetus from the maternal immune system. 28, 29 Indeed, critical roles for the PD-L1 in fetomaternal tolerance have been demonstrated in a mouse model. PD-L1-deficient female mice exhibited decreased allogeneic fetal survival rates compared with littermates and heterozygote controls. 30 It is not surprising that choriocarcinoma, a malignant trophoblastic tumor, showed strong PD-L1 expression among germ cell tumors. These observations indicate that PD-L1 could be a supplementary marker to identify choriocarcinoma or trophoblastic elements in other germ cell tumors.
PD-L1 was consistently expressed in normal peripheral nerves. The physiological roles of PD-L1 in nervous tissue have not been fully explored. However, PD-L1 was indicated as a suppressor for the inflammatory response and neuropathic pain occurring after peripheral 
TABLE 4. PD-L1 Expression in Gastric Adenocarcinomas
Gastric Adenocarcinoma Subtypes (n = 180 in MMR Analysis; n = 190 in EBER Analysis)
PD-L1 (Tumor Cells; %)
MMR preserved (n = 165) 12.1 MMR deficient (n = 15) 46.7** EBER negative (n = 179) 12.3 EBER positive (n = 11) 45.5* Fisher exact test. *P < 0.05. **P < 0.01. nerve injury in PD-L1 knockout mice. 31 Among neoplasms, schwannomas showed consistent PD-L1 expression, whereas neurofibroma and MPNST showed rarer and weaker expression. Schwannoma mimics such as gastrointestinal stromal tumor, fibrous histiocytoma, perineurioma, solitary fibrous tumor, and meningioma were almost always negative. These results indicate that PD-L1 could have a role in the differential diagnosis of schwannoma. However, it should be considered that minority of melanotic and desmoplastic melanomas are also positive for PD-L1. In analyzed thymic tumors, 79% and 38% of thymoma and thymic carcinoma cells showed PD-L1 expression, respectively (Table 2) . Recently, 2 groups reported frequent PD-L1 expression in thymic tumors. 24, 25 One study showed that 68% of thymoma and 75% of thymic carcinoma neoplastic cells were positive for PD-L1 using rabbit monoclonal antibody 15 from Sino Biological (Beijing, China). This study also showed that PD-L1 highexpressing thymic tumors had a significantly worse overall survival in an adjusted (age/sex) analysis. 25 However, other study using E1L3N rabbit monoclonal antibody showed that 23% of thymomas and 70% of thymic carcinomas were positive for PD-L1, and PD-L1 positivity was not a significantly negative factor for overall survival in a multivariate analysis. 24 Thus, additional studies are needed to explain these divergent results.
Recently, gastric cancers were classified into 4 categories such as EBV-infected, microsatellite unstable, genomically stable, and chromosomally unstable tumors, by the comprehensive molecular analysis by the Cancer Genome Atlas (TCGA) project. 32 It was also found that EBV-infected tumors carry PIK3CA mutations, extreme DNA hypermethylation, and amplification of 9p24 region including JAK2, PD-L1, and PD-L2. This study confirmed the positive correlation of EBER and PD-L1 expression by typical methods such as in situ hybridization and immunohistochemistry (Table 4 ). Our study also showed a positive correlation between MMR deficiency and PD-L1 expression (Table 4) and that only 11% of other 2 types (genomically stable and chromosomally unstable tumors) were positive for PD-L1.
Aberrantly activated oncogenic signals due to PTEN loss, EGFR mutation, or ALK translocation were reported to induce PD-L1 overexpression in neoplastic cells. 14, 15, 33 It was also reported that ALCLs, carrying nucleophosmin/ anaplastic lymphoma kinase (ALK) translocation, were induced to PD-L1 overexpression through the nucleophosmin/ALK-STAT3 axis activation. 14 However, no correlation between PD-L1 and ALK expression status was demonstrated in this study (Supplementary Table S4 , Supplemental Digital Content 4, http://links.lww.com/ PAS/A363). Moreover, 9 of 10 ALK-negative ALCLs also showed strong PD-L1 expression. These results strongly indicated that there could be alternative pathway(s) regulating PD-L1 expression in ALCLs.
EBV is significantly associated with classical Hodgkin lymphoma. 34 It was reported that the induction of the EBV latent membrane proteins, latent membrane protein 1 (LMP1) or LMP2a, in normal germinal center B cells is sufficient to mimic a Hodgkin Reed-Sternberg celllike phenotype. 35, 36 Furthermore, LMP1 was reported to increase PD-L1 expression by upregulating its promoter activity through a JAK3-dependent manner. 37 Thus, EBER-positive classical Hodgkin lymphomas would be 38 These EBER-negative classical Hodgkin lymphoma cases might carry genomic amplification of the 9p24 region.
In other viral infections, HPV infection was reported to correlate with PD-L1 expression in squamous cell carcinomas of the tonsil. 39 In this study, 90% and 93% of tonsil squamous cell carcinoma showed PD-L1 and p16 expression, respectively. However, no statistical correlation was detected between PD-L1 and p16 expression (Table 2 and Supplementary Table S2 , Supplemental Digital Content 2, http://links.lww.com/PAS/A361).
It has been reported that PD-L1-expressing dendritic cells or TAIs are able to induce tumor immune evasion. [16] [17] [18] In the current study, seminoma and various carcinomas often showed such PD-L1-positive cells, whereas mesenchymal tumors were less frequently associated with PD-L1-expressing inflammatory cells (Supplementary Table S1 , Supplemental Digital Content 1, http://links.lww.com/ PAS/A360). Clinical or experimental investigation is needed to determine whether tumors with PD-L1-positve TAIs could be targets for immune checkpoint inhibition therapy.
In clinical trials, PD-1/PD-L inhibitors were introduced to the treatment of the patients with PD-L1-expressing tumors, such as melanoma, NSCLC, renal cell cancer, and Hodgkin lymphoma. [19] [20] [21] [22] Recently, advanced squamous cell and other non-squamous cell NSCLC patients were treated with nivolumab or docetaxel to compare their antitumor activity. 20, 21 Both squamous cell and nonsquamous cell NSCLC patients treated by nivolumab showed significantly better overall survival, response rate, and progression-free survival than docetaxel-treated patients. However, the hazard ratio for death was lower in squamous cell carcinoma patients (0.59 [95% confidence interval, 0.44-0.79], P < 0.001) than in non-squamous cell NSCLC patients (0.73 [96% confidence interval, 0.59-0.89], P = 0.002) indicating better treatment success for squamous cell NSCLC patients. In addition, refractory Hodgkin lymphoma patients showed a response to nivolumab treatment. 19 These results indicate that PD-L1-expressing tumors, such as germ cell tumors with trophoblastic differentiation and MPNSTs, might be successfully treated by PD-1/PD-L checkpoint inhibitors.
In conclusion, PD-L1 immunohistochemistry using rabbit monoclonal antibody clone E1L3N might have a role in diagnostic immunophenotyping of germ cell tumors with trophoblastic differentiation, schwannoma, thymoma, 
